An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease

NCT00269854 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Infliximab 5 mg/kg
DRUG: Infliximab 10 mg/kg
DRUG: Infliximab 20 mg/kg
DRUG: Placebo

Sponsor

Centocor, Inc.